Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

Phase 2 Completed 91 enrolled Brii Biosciences Limited VBI Vaccines Inc. · collab Vir Biotechnology, Inc. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection

Timeline

Start: 2021-04-12
Primary completion: 2023-07-04
Completion: 2023-07-04

Publications

Ji Y, Le Bert N, Lai-Hung Wong G, Douglas MW, Lee A, Zhu C, Wang B, Lv J, Li D, Tan Y, Ma H, Chen J, Chen X, Zhu Q, Yuen MF, Bertoletti A. The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses. Gastroenterology. 2025 Jul;169(1):136-149. doi: 10.1053/j.gastro.2025.02.016. Epub 2025 Mar 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BRII-179	Vaccine	—	Intramuscular
Subject	IFN-α	Unknown	—	Intramuscular
Subject	VIR-2218	Small interfering RNA (siRNA)	—	Subcutaneous

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

Summary

Timeline

Publications

Drugs

Indications